BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10190795)

  • 1. The evolving role of paclitaxel for patients with carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):129-33. PubMed ID: 10190795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current role and future prospects of paclitaxel in the treatment of small cell lung cancer.
    Hainsworth JD; Greco FA
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):60-6. PubMed ID: 10190785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carcinoma of unknown primary site.
    Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
    Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel in salvage therapy for germ cell tumors.
    Motzer RJ
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel via 1-hour infusion: clinical experience.
    Greco FA; Hainsworth JD
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):91-3. PubMed ID: 9007131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review and outlook for the role of paclitaxel in urothelial carcinoma.
    Vaughn DJ
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):117-22. PubMed ID: 10190793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel in the treatment of esophageal cancer.
    Weiner LM
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):106-8. PubMed ID: 10190790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel pharmacology and other tumor types.
    Rowinsky EK
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-1-S19-12. PubMed ID: 9427257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
    Hainsworth JD; Spigel DR; Litchy S; Greco FA
    J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-based treatment of lymphoma.
    Younes A
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):123-8. PubMed ID: 10190794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel in the treatment of hormone-refractory prostate cancer.
    Smith DC; Pienta KJ
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):109-11. PubMed ID: 10190791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
    Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD
    Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
    Lilenbaum RC; Herndon JE; List MA; Desch C; Watson DM; Miller AA; Graziano SL; Perry MC; Saville W; Chahinian P; Weeks JC; Holland JC; Green MR
    J Clin Oncol; 2005 Jan; 23(1):190-6. PubMed ID: 15625373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene.
    Calvert AH; Ghokul S; Al-Azraqi A; Wright J; Lind M; Bailey N; Highley M; Siddiqui N; Lunec J; Sinha D; Boddy A; Roberts T; Fenwick J
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):90-4. PubMed ID: 10190788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
    Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
    Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer.
    Ettinger DS
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):148-50. PubMed ID: 10210554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.